Literature DB >> 7827357

Blood levels of insulin-like growth factors I and II in neonates of non-insulin-dependent diabetic rats.

J Levy1, J R Gavin.   

Abstract

Circulating levels of insulin like growth factor I (IGF-I) and insulin like growth factor II (IGF-II) were evaluated in plasma samples during the first 72 h of life in neonates of diabetic and control mother rats. Diabetes had been induced in the diabetic dams by streptozotocin at 2 days of age. The rats developed non-insulin dependent diabetes (at 6 weeks of age) and became pregnant at 11 weeks of age. Maternal blood glucose levels were higher in the diabetic mothers (P < 0.05) during the last two-thirds of gestation. Complications occurred at the end of 7.1% of the diabetic pregnancies but none of the controls. Analysis of neonates plasma glucose, IGF-I, and IGF-II concentrations in the first 12, 24, 48, and 72 h after birth revealed higher glucose levels in neonates of diabetic mothers at 72 h compared with controls (118 +/- 7 vs 85 +/- 5 mg/dl, P < 0.05) but there was no difference in IGF-I or IGF-II levels between the groups at any time point. Thus, acquired impaired glucose homeostasis may be seen in neonates of mildly diabetic mothers at early stages of their life but their circulating insulin-like growth factors levels are normal. These data do not support the proposition that fetal IGF-I and -II affect the outcome of pregnancies complicated by mild diabetes in the rodent.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7827357     DOI: 10.1007/bf00570373

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  23 in total

1.  Non-insulin-dependent diabetes mellitus: interplay between B-cell inadequacy and insulin resistance.

Authors:  G C Weir
Journal:  Am J Med       Date:  1982-10       Impact factor: 4.965

2.  Effect of insulin on glucose utilization in epitrochlearis muscle of rats with streptozocin-induced NIDDM.

Authors:  I E Karl; J R Gavin; J Levy
Journal:  Diabetes       Date:  1990-09       Impact factor: 9.461

3.  Impaired insulin action in rats with non-insulin-dependent diabetes.

Authors:  J Levy; J R Gavin; A Fausto; R L Gingerich; L V Avioli
Journal:  Diabetes       Date:  1984-09       Impact factor: 9.461

4.  The 1986 McCollum award lecture. Fuel-mediated teratogenesis during early organogenesis: the effects of increased concentrations of glucose, ketones, or somatomedin inhibitor during rat embryo culture.

Authors:  N Freinkel; D L Cockroft; N J Lewis; L Gorman; S Akazawa; L S Phillips; G E Shambaugh
Journal:  Am J Clin Nutr       Date:  1986-12       Impact factor: 7.045

5.  Hormone-specific defect in insulin regulation of (Ca2+ + Mg2+)-adenosine triphosphatase activity in kidney membranes from streptozocin non-insulin-dependent diabetic rats.

Authors:  J Levy; D Rempinski; T H Kuo
Journal:  Metabolism       Date:  1994-05       Impact factor: 8.694

6.  Somatomedin inhibitors from diabetic rat serum alter growth and development of mouse embryos in culture.

Authors:  T W Sadler; L S Phillips; W Balkan; S Goldstein
Journal:  Diabetes       Date:  1986-08       Impact factor: 9.461

7.  Mineral homeostasis in neonates of streptozotocin-induced noninsulin-dependent diabetic rats and in their mothers during pregnancy and lactation.

Authors:  J Levy; J R Gavin; M J Scott; L V Avioli
Journal:  Bone       Date:  1987       Impact factor: 4.398

8.  Malformations in infants of diabetic mothers.

Authors:  J L Mills
Journal:  Teratology       Date:  1982-06

9.  Studies of insulin-like growth factor -I and -II by specific radioligand assays in umbilical cord blood.

Authors:  P D Gluckman; J J Johnson-Barrett; J H Butler; B W Edgar; T R Gunn
Journal:  Clin Endocrinol (Oxf)       Date:  1983-09       Impact factor: 3.478

10.  Increased incidence of congenital malformations in the offspring of diabetic rats and their prevention by maternal insulin therapy.

Authors:  U Eriksson; E Dahlström; K S Larsson; C Hellerström
Journal:  Diabetes       Date:  1982-01       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.